Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

Paratesticular rhabdomyosarcoma in children and adolescents-Outcome and patterns of relapse when utilizing a nonsurgical strategy for lymph node staging: Report from the International Society of Paediatric Oncology (SIOP) Malignant Mesenchymal Tumour 89 a

(2017) Timothy Rogers et al.   PEDIATRIC BLOOD & CANCER

Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group

(2017) Erin R. Rudzinski et al.   PEDIATRIC BLOOD & CANCER

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

(2016) Brenda J. Weigel et al.   JOURNAL OF CLINICAL ONCOLOGY

Does aggressive local treatment have an impact on survival in children with metastatic rhabdomyosarcoma?

(2015) M. Ben Arush et al.   EUROPEAN JOURNAL OF CANCER

High incidence of regional and in-transit lymph node metastasis in patients with alveolar rhabdomyosarcoma

(2013) Yoshihiro Nishida et al.   International Journal of Clinical Oncology

Histologic and Clinical Characteristics Can Guide Staging Evaluations for Children and Adolescents With Rhabdomyosarcoma: A Report From the Children's Oncology Group Soft Tissue Sarcoma Committee

(2013) Aaron R. Weiss et al.   JOURNAL OF CLINICAL ONCOLOGY

PAX-FOXO1fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report

(2013) Stephen X. Skapek et al.   PEDIATRIC BLOOD & CANCER

Randomized Comparison of Intensified Six-Drug Versus Standard Three-Drug Chemotherapy for High-Risk Nonmetastatic Rhabdomyosarcoma and Other Chemotherapy-Sensitive Childhood Soft Tissue Sarcomas: Long-Term Results From the International Society of Pediatric Oncology MMT95 Study

(2012) Odile Oberlin et al.   JOURNAL OF CLINICAL ONCOLOGY

PAX3/FOXO1Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification

(2012) Edoardo Missiaglia et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Significance and Tumor Biology of Regional Lymph Node Disease in Patients With Rhabdomyosarcoma: A Report From the Children's Oncology Group

(2011) David A. Rodeberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Factors After Relapse in Nonmetastatic Rhabdomyosarcoma: A Nomogram to Better Define Patients Who Can Be Salvaged With Further Therapy

(2011) Julia C. Chisholm et al.   JOURNAL OF CLINICAL ONCOLOGY

Regional Nodal Involvement and Patterns of Spread Along In-Transit Pathways in Children With Rhabdomyosarcoma of the Extremity: A Report From the Children's Oncology Group

(2010) Trang H. La et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?

(2009) Arnold C. Paulino et al.   PEDIATRIC BLOOD & CANCER

Prognostic Factors in Metastatic Rhabdomyosarcomas: Results of a Pooled Analysis From United States and European Cooperative Groups

(2008) Odile Oberlin et al.   JOURNAL OF CLINICAL ONCOLOGY